Protoporphyrin IX

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Tuesday, December 12, 2023
Quality of life, Anemia, Protoporphyrin IX, Bitopertin, Erythropoietic protoporphyria, IRON, Ruxolitinib, Disc, ASH, Photosensitivity, Light, Growth, XLP, Patient, Safety, EPP, Surveying

“This has been a tremendous ASH meeting for Disc, as we presented data across our two most advanced programs.

Key Points: 
  • “This has been a tremendous ASH meeting for Disc, as we presented data across our two most advanced programs.
  • “With these results and the positive initial efficacy data from the DISC-0974 myelofibrosis study that we presented earlier today, Disc is preparing to enter its next stage of growth.
  • Earlier today, Disc also presented initial positive data from the ongoing phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia.
  • Bitopertin and DISC-0974 are investigational agents and are not approved for use as a therapy in any jurisdiction worldwide.

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

Retrieved on: 
Thursday, November 2, 2023
IRON, EPP, AURORA, Ruxolitinib, Society, Sunlight, ASH, Interim, Protoporphyrin IX, Anemia, PPIX, Exposition, Pain, Patient, Pharmaceutical industry, Disc

“We look forward to presenting updated interim data from all patients enrolled in the BEACON study at the upcoming ASH meeting, as well as preliminary clinical data from initial cohorts of both DISC-0974 anemia studies.” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.

Key Points: 
  • “We look forward to presenting updated interim data from all patients enrolled in the BEACON study at the upcoming ASH meeting, as well as preliminary clinical data from initial cohorts of both DISC-0974 anemia studies.” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.
  • “In addition, we’re pleased to announce the full enrollment of both the BEACON and AURORA studies of bitopertin in patients with EPP.
  • The full abstracts are now available through the ASH conference website.
  • Please register for management’s webcast on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/).

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

Retrieved on: 
Friday, June 9, 2023
EPIQ, Sodium- and chloride-dependent glycine transporter 1, Protoporphyrin IX, European Hematology Association, Metallicity, Disc, Week, EPP, Bitopertin, Quality of life, First grade, Pain, Congress, Sunlight, IRON, Patient, Erythropoietic protoporphyria, EHA, XLP, Photosensitivity, Poster, Safety, Disease, Pharmaceutical industry, Medical device, Sewage treatment, PPIX

The initial trial data demonstrated consistent decreases in PPIX, significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.

Key Points: 
  • The initial trial data demonstrated consistent decreases in PPIX, significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.
  • “We’re delighted to share these initial, positive data from BEACON, which provide the first clinical evidence supporting our therapeutic hypothesis of bitopertin in EPP.
  • Due to batch processing of samples, the data cutoff for PPIX data was April 7, 2023.
  • Management will host a call to review the presented data on Friday, June 9th at 7:30 am ET.